SAN FRANCISCO--(BUSINESS WIRE)--Javelin Pharmaceuticals Inc. (AMEX: JAV) today will present results of a new Phase I study of Dyloject™ (injectable diclofenac sodium) demonstrating minimal effects upon platelet function at a clinically effective dose. In contrast, aspirin and ketorolac each impaired platelet aggregation significantly. Inhibition of platelet aggregation with Dyloject and another comparator, Cataflam (an oral formulation of diclofenac) was detectable but not clearly outside the normal range, although Cataflam inhibited platelet aggregation slightly more than Dyloject. These findings will be presented by Javelin’s CEO/CMO Dr. Daniel Carr as part of a broader corporate update about Javelin at the 26th Annual JPMorgan Healthcare Conference in San Francisco.
